RE: RENAL Health: Advancing Phase 2 and Phase 3 stud ies of the company’s targeted C3 therapy in C3G / IC-MPGN , rare kidney diseases with no approved medicines . First patient in Phase 2 study expected to be dosed by the end of th e year P otentially registrational Phase 2 […]
Click here to view original web page at www.globenewswire.com